current
evalu
human
immunodefici
viru
hiv
vaccin
vector
compel
reason
develop
rvsv
vaccin
vector
includ
low
seropreval
human
abil
infect
robustli
express
foreign
antigen
broad
rang
cell
vigor
growth
continu
cell
line
use
vaccin
manufactur
numer
preclin
studi
rvsv
vector
express
antigen
varieti
human
pathogen
demonstr
versatil
flexibl
potenti
efficaci
rvsv
vaccin
platform
administ
nonhuman
primat
nhp
rvsv
vector
express
gag
env
elicit
robust
cellular
humor
immun
respons
anim
immun
rvsv
vector
express
simian
immunodefici
viru
siv
gag
hiv
env
protect
aid
challeng
pathogen
sivhiv
recombin
howev
result
exploratori
neurovirul
studi
nhp
indic
prototyp
rvsv
vector
might
adequ
attenu
widespread
use
human
popul
address
safeti
concern
varieti
differ
attenu
strategi
design
produc
rang
attenu
rvsv
vector
current
investig
addit
modif
attenu
rvsv
vector
upregul
express
antigen
coexpress
molecular
adjuv
also
develop
effort
balanc
immunogen
attenu
host
without
major
role
viru
spread
contrast
circumstanti
evid
bite
insect
major
viru
reservoir
vector
diseas
anim
mani
vesiculovirus
recov
natur
bloodsuck
insect
bite
transmiss
vsv
ind
chandipura
laboratori
anim
experiment
infect
mosquito
sandfli
demonstr
addit
natur
infect
occur
sentinel
anim
expos
area
known
viru
activ
hypothesi
insect
major
vsv
reservoir
support
demonstr
vertic
transmiss
experiment
infect
sand
fli
natur
would
allow
viru
propag
persist
insect
popul
without
need
intermedi
host
vsv
infect
human
rare
occur
anim
handler
veterinarian
come
close
contact
infect
livestock
inadvert
exposur
laboratori
personnel
common
portal
infect
human
skin
mucou
membran
nose
mouth
eye
although
also
serolog
evid
suggest
vesiculovirus
may
directli
transmit
human
insect
bite
human
infect
vsv
either
asymptomat
may
lead
diseas
symptom
includ
myalgia
headach
fever
resolv
day
without
complic
standard
vsv
particl
bulletshap
nm
compris
ribonucleoprotein
core
surround
lipid
envelop
deriv
host
cell
plasma
membran
viru
genom
singl
strand
negativesens
rna
encod
five
major
viral
protein
fig
n
protein
abund
viru
protein
express
infect
cell
associ
close
genom
rna
form
viral
nucleocapsid
function
templat
viral
transcript
replic
p
l
protein
associ
form
function
viral
rna
polymeras
perform
transcriptas
replicas
function
protein
abund
protein
viru
particl
multipl
function
infect
cell
includ
viru
bud
inhibit
host
cell
gene
express
regul
viral
transcript
g
protein
type
transmembran
glycoprotein
form
trimer
spikelik
structur
viru
surfac
facilit
viru
attach
host
cell
receptor
uptak
endocytosi
ph
g
protein
undergo
conform
chang
result
fusion
viral
envelop
membran
endosom
vesicl
releas
viral
nucleocapsid
viral
rna
polymeras
host
cell
cytoplasm
initi
replic
cycl
engag
uniqu
transcript
promot
nucleocapsid
templat
rna
polymeras
initi
mrna
transcript
proce
toward
genom
termin
reiniti
transcript
gene
junction
result
product
five
discreet
viral
mrna
vmrna
process
transcriptas
complex
occasion
detach
nucleocapsid
templat
intergen
junction
must
return
promot
reiniti
transcript
result
pronounc
gradient
vmrna
express
fig
transcript
gradient
allow
viru
express
individu
protein
optim
level
viral
replic
exampl
l
gene
encod
viral
rna
polymeras
catalyt
protein
need
rel
small
amount
distal
transcript
promot
transcrib
low
effici
infect
cell
convers
n
gene
encod
major
structur
protein
requir
abund
nucleocapsid
format
immedi
adjac
transcript
promot
effici
transcrib
time
initi
primari
mrna
transcript
genom
replic
also
begin
mechan
respons
switch
rna
polymeras
transcript
replic
mode
fulli
understood
although
number
hypothes
propos
nucleocapsid
also
function
templat
genom
replic
transcript
viral
replicas
initi
rna
synthesi
exact
genom
proce
ignor
transcript
stop
start
signal
produc
fulllength
posit
sens
copi
viral
genom
nascent
positiveand
negativesens
genom
rna
encapsid
n
protein
cooper
corepl
manner
result
ribonucleprotein
complex
subsequ
function
templat
genom
amplif
mrna
transcript
increas
avail
amplifi
viral
genom
templat
secondari
transcript
lead
rapid
increas
abund
viral
protein
need
matur
viru
particl
product
viru
assembl
process
understood
complet
avail
data
indic
viral
nucleocapsid
associ
region
plasma
membran
enrich
g
protein
nucleocapsid
condens
form
transcript
inact
process
appear
primarili
driven
protein
plasma
membran
contain
g
protein
envelop
underli
viral
nucleocapsid
matur
viru
particl
bud
cell
surfac
g
protein
cytoplasm
tail
ct
appear
essenti
role
viru
bud
enhanc
effici
process
matur
viru
particl
contain
viral
rna
polymeras
necessari
propag
suscept
cell
recent
direct
manipul
vsv
genom
imposs
due
instabl
singlestrand
rna
difficulti
defin
condit
would
allow
recoveri
infecti
viru
genom
cdna
howev
result
pioneer
work
carri
number
laboratori
recoveri
process
known
viru
rescu
develop
approxim
year
ago
rescu
procedur
involv
transfect
suscept
cell
plasmid
express
viru
n
p
l
protein
fulllength
posit
sens
genom
rna
fig
n
p
l
protein
associ
nascent
genom
rna
initi
viru
replic
transcript
produc
infecti
viru
progeni
abil
rescu
vsv
clone
cdna
allow
fundament
question
viru
replic
address
also
enabl
ration
design
develop
recombin
vsv
rvsv
vaccin
vector
mani
aspect
vsv
biolog
support
develop
rvsv
vaccin
vector
treatment
prevent
human
diseas
viru
genom
simpli
organ
discreet
transcript
unit
tu
express
viral
protein
nucleotid
signal
sequenc
fig
vsv
genom
organ
particl
structur
morpholog
vsv
genom
encod
five
major
viral
protein
express
five
discreet
tu
singl
transcript
promot
genom
replic
promot
resid
within
leader
sequenc
antigenom
replic
promot
resid
within
trailer
sequenc
consensu
transcript
start
stop
signal
begin
end
tu
respect
result
synthesi
five
vmrna
genom
replic
occur
positivesens
antigenom
intermedi
b
vsv
particl
bulletshap
contain
ribonucleoprotein
core
surround
lipid
envelop
deriv
host
cell
plasma
membran
n
protein
close
associ
genom
rna
form
viral
nucleocapsid
viral
rna
polymeras
compris
complex
p
l
protein
packag
insid
viru
particl
g
protein
trimer
form
spikelik
project
viral
envelop
attach
viru
particl
host
cell
receptor
electron
micrograph
show
vsv
particl
stain
phosphotungst
acid
reprint
permiss
rose
whitt
involv
control
viral
gene
express
defin
accordingli
one
addit
tu
encod
foreign
protein
ad
vsv
genom
robustli
express
control
transcript
promot
furthermor
abund
foreign
protein
express
modul
depend
proxim
extra
tu
rel
transcript
promot
unpublish
data
although
mutat
frequenc
vsv
high
addit
foreign
gene
essenti
viru
replic
consensu
sequenc
foreign
protein
open
read
frame
orf
maintain
mani
round
amplif
ensur
preserv
target
antigen
vaccin
manufactur
process
abil
rvsv
vaccin
vector
propag
vigor
qualifi
continu
cell
line
also
facilit
industri
scale
manufactur
vaccin
prepar
human
infect
rare
vsv
seropreval
gener
popul
low
therefor
preexist
immun
like
factor
affect
efficaci
futur
rvsv
vaccin
vector
may
case
propos
viral
vaccin
vector
inde
exist
mani
differ
vesiculoviru
serotyp
may
exploit
design
multipl
rvsv
vaccin
vector
prevent
treatment
mani
differ
diseas
vsv
caus
obviou
sign
diseas
parenter
administr
either
livestock
nonhuman
primat
nhp
rvsv
vector
anticip
innocu
human
administ
parenter
desir
safeti
featur
includ
lack
dna
intermedi
viral
replic
cytoplasm
site
genom
replic
reduc
likelihood
viral
nucleic
acid
integr
host
cell
dna
furthermor
vector
genom
stabil
enhanc
encapsid
undergo
recombin
fig
vsv
mrna
transcript
gradient
gene
proxim
transcript
promot
transcrib
abundantli
proxim
gene
gradient
mrna
transcript
aris
rna
polymeras
complex
often
detach
templat
intergen
junction
reiniti
transcript
transcript
promot
fig
rescu
rvsv
genom
cdna
viru
rescu
initi
cotransfect
plasmid
step
encod
fulllength
viral
genom
transact
viral
polypeptid
rna
polymeras
introduc
cell
varieti
differ
method
mediat
rna
synthesi
cell
cytoplasm
earliest
stage
rescu
produc
copi
viral
genom
rna
transcript
encod
transact
polypeptid
n
p
l
need
promot
de
novo
assembl
nucleocapsid
step
function
nucleocapsid
subsequ
serv
templat
genom
replic
transcript
vmrna
accumul
viral
protein
step
trigger
ensu
event
viral
replic
cycl
includ
viru
assembl
step
bud
step
prototyp
rvsv
vector
foreign
gene
express
tu
insert
posit
viral
genom
fig
g
l
gene
insert
site
chosen
minim
perturb
stoichiometri
viral
protein
express
modul
distanc
gene
transcript
promot
l
protein
catalyt
function
displac
l
gene
one
addit
tu
promot
view
conserv
genom
alter
advers
affect
viral
replic
allow
adequ
foreign
protein
express
gener
immun
respons
rational
support
vitro
growth
studi
show
minim
reduct
peak
viru
titer
vector
contain
extra
foreign
gene
g
l
gene
furthermor
level
foreign
protein
express
suffici
elicit
robust
antigenspecif
immun
respons
singl
inocul
mice
rabbit
case
primari
immun
respons
could
boost
second
dose
homolog
vaccin
month
later
howev
durabl
neutral
antibodi
usual
elicit
vsv
surfac
glycoprotein
singl
vaccin
replicationcompet
rvsv
vector
glycoprotein
exchang
vector
design
allow
effect
boost
immun
respons
target
antigen
exchang
vector
gener
switch
ind
serotyp
g
gene
prime
vector
either
vsv
nj
chandipura
serotyp
g
gene
boost
vector
view
flexibl
rvsv
vector
platform
encourag
data
preclin
studi
experiment
influenza
vaccin
rvsv
vector
express
antigen
varieti
human
pathogen
develop
test
preclin
anim
challeng
model
tabl
vector
express
antigen
hepat
c
viru
hcv
hantaviru
mycobacterium
tuberculosi
assess
preclin
immunogen
studi
first
nhp
experi
evalu
rvsv
vector
system
human
immunodefici
viru
hiv
conduct
dr
john
rose
colleagu
yale
pioneer
studi
rhesu
macaqu
immun
combin
two
prototyp
rvsv
vector
express
env
fusion
polypeptid
simian
immunodefici
viru
siv
gag
protein
vaccin
vector
administr
combin
intramuscular
intranas
rout
clearli
demonstr
abil
rvsv
vector
elicit
potent
antigenspecif
cellmedi
immun
respons
nhp
addit
studi
also
clearli
demonstr
first
time
abil
rvsv
vector
express
env
gag
protein
provid
highli
signific
protect
aid
intraven
heterolog
sivhiv
shiv
challeng
studi
seven
macaqu
receiv
rvsv
express
hivenv
sivgag
remain
diseasefre
shiv
challeng
year
j
rose
person
commun
comparison
eight
control
macaqu
either
unimmun
immun
labadapt
rvsv
express
influenza
hemagglutinin
ha
progress
aid
averag
time
month
j
rose
person
commun
protect
aid
studi
correl
larg
differ
peak
viral
load
low
undetect
viral
load
set
point
preserv
cell
vaccine
rel
control
encourag
level
postchalleng
vaccin
efficaci
suggest
rvsv
vector
express
hiv
gene
might
effect
aid
vaccin
human
addit
demonstr
postchalleng
efficaci
nhp
rvsvbase
vaccin
advantag
suggest
may
ideal
suit
develop
worldwid
prophylact
vaccin
notabl
rvsvbase
vaccin
vector
least
anim
model
safe
effect
administ
via
mucos
rout
shown
sever
anim
model
exampl
singl
intranas
inocul
rvsv
vector
express
influenza
viru
ha
protein
mice
herp
simplex
viru
hsv
type
glycoprotein
mice
measl
viru
ha
protein
cotton
rat
complet
protect
anim
mucos
challeng
correspond
wildtyp
pathogen
recent
laboratori
systemat
compar
immunogen
rvsv
vaccin
vector
given
either
intramuscular
intranas
inocul
effort
determin
rout
vaccin
administr
optim
induc
humor
cellular
immun
respons
rhesu
macaqu
result
demonstr
mamua
mhc
class
iposit
macaqu
vaccin
combin
studi
yet
conduct
directli
evalu
safeti
rvsv
vector
administ
human
mention
previous
infect
field
isol
cell
cultureadapt
vsv
associ
signific
ill
human
furthermor
cours
numer
immunogen
safeti
studi
perform
wyeth
unpublish
data
nhp
inocul
either
intranas
intramuscularli
high
dose
plaqueform
unit
cell
cultureadapt
vsv
varieti
rvsv
vector
without
advers
effect
anim
maintain
normal
blood
chemistri
blood
cell
count
bodi
weight
inocul
viru
show
sign
characterist
vesicular
lesion
observ
nasal
lingual
epithelia
although
studi
describ
indic
rvsv
vaccin
vector
could
administ
safe
human
addit
safeti
studi
would
requir
proceed
clinic
studi
replicationcompet
viral
vaccin
histor
subject
stringent
safeti
test
includ
direct
inocul
viru
central
nervou
system
suscept
nhp
measur
neurovirul
nv
potenti
although
vaccin
vector
describ
attenu
rel
vsv
field
isol
replicationcompet
subject
stringent
safeti
test
use
live
attenu
vaccin
virus
reason
prototyp
rvsv
vector
number
close
relat
rvsv
vector
express
gag
protein
test
exploratori
nhp
nv
studi
studi
also
warrant
histor
data
show
vsv
field
isol
tissu
cultureadapt
vsv
strain
neurotroph
neurovirul
rodent
vsv
serial
passag
mous
brain
found
neurovirul
livestock
nhp
inocul
intracrani
rout
nv
potenti
vaccin
vector
test
direct
intrathalam
inocul
cynomolgu
macaqu
accord
procedur
use
assess
product
lot
mump
viru
vaccin
result
exploratori
studi
show
prototyp
rvsv
vector
express
gag
much
attenu
cell
cultureadapt
wildtyp
vsv
retain
level
residu
nv
would
like
unaccept
regulatori
agenc
j
erik
johnson
et
al
submit
public
address
safeti
concern
rais
outcom
exploratori
nhp
nv
studi
varieti
distinct
strategi
investig
attenu
growth
virul
rvsv
vector
multipl
approach
pursu
imposs
predict
attenu
strategi
would
provid
optim
balanc
safeti
immunogen
abil
attenu
vitro
growth
virul
rvsv
move
n
gene
first
posit
genom
downstream
locat
clearli
demonstr
stepwis
transloc
n
gene
away
transcript
promot
lead
increment
reduct
n
protein
express
therebi
limit
nucleocapsid
format
fig
nucleocapsid
function
templat
mrna
transcript
genom
replic
part
virion
core
limit
nucleocapsid
lead
decreas
viral
protein
synthesi
genom
amplif
format
matur
viru
particl
addit
provid
mean
attenu
rvsv
vector
increment
anoth
attract
featur
attenu
strategi
known
genet
stabil
n
gene
transloc
greatli
elimin
likelihood
revers
truncat
ct
region
g
protein
also
use
attenu
vitro
growth
vivo
virul
rvsv
vector
wildtyp
g
protein
ct
region
amino
acid
length
howev
ct
truncat
either
one
nine
amino
acid
respect
fig
peak
viru
titer
obtain
cell
cultur
reduc
result
virus
less
pathogen
mice
intranas
inocul
attenu
mechan
like
involv
impair
interact
viral
ribonucleoprotein
core
truncat
g
protein
ct
viral
morphogenesi
lead
reduct
effici
viru
particl
assembl
seen
n
gene
transloc
g
protein
ct
truncat
also
give
rise
viru
stabl
attenu
phenotyp
replac
delet
sequenc
encod
part
protein
improb
vsv
protein
play
key
role
develop
viru
induc
cell
cytopatholog
cell
death
mutat
rvsv
gene
delay
diminish
cytopath
effect
infect
cell
describ
mutat
ablat
express
two
overlap
infram
polypeptid
express
protein
mrna
initi
protein
synthesi
intern
aug
fig
polypeptid
may
role
develop
cell
cytopatholog
inhibit
nuclear
export
cellular
mrna
disrupt
cell
cytoskeleton
gene
mutant
also
much
less
pathogen
mice
unpublish
data
histor
vsv
temperaturesensit
ts
mutant
isol
either
result
random
point
mutat
commonli
chemic
mutagenesi
condit
mutant
usual
propag
robustli
permiss
temperatur
poorli
defin
nonpermiss
temperatur
temperatur
nasal
epithelium
typic
lower
core
bodi
temperatur
select
incorpor
ts
mutat
produc
rvsv
vector
replic
vigor
serv
vector
intranas
stepwis
transloc
n
gene
away
transcript
promot
lead
increment
attenu
viru
growth
vitro
vivo
method
attenu
reli
downregul
n
protein
express
due
transcript
gradient
fig
attenu
rvsv
g
protein
truncat
truncat
ct
region
rvsv
g
protein
amino
acid
either
nine
one
amino
acid
progress
attenu
viru
growth
vitro
vivo
believ
viral
morphogenesi
advers
affect
due
impair
interact
shorter
ct
underli
viral
core
protein
fig
molecular
mechan
ts
attenu
often
clearli
defin
probabl
involv
impair
protein
fold
instabl
nonpermiss
temperatur
case
replicationcompet
rvsv
vector
prove
inadequ
attenu
use
human
propagationincompet
rvsv
vector
also
develop
vector
restrict
singl
round
replic
unabl
spread
beyond
primari
infect
cell
one
vector
entir
g
gene
delet
therefor
requir
g
protein
transcomplement
propag
infecti
viru
particl
vitro
fig
anoth
relat
vector
g
protein
ectodomain
delet
g
stem
retain
ct
region
transmembran
domain
amino
acid
membran
proxim
ectodomain
fig
vector
also
propagationdefect
requir
g
protein
tran
product
infecti
particl
vitro
express
truncat
form
g
protein
g
stem
enhanc
overal
yield
progeni
viru
particl
vitro
compar
vector
entir
g
gene
delet
perhap
due
increas
concentr
g
protein
ct
cell
plasma
membran
facilit
viru
assembl
bud
although
propagationdefect
viru
offer
obviou
safeti
advantag
difficulti
provid
adequ
quantiti
complement
g
protein
allow
effici
vector
amplif
industri
scale
manufactur
possibl
limit
strategi
gave
rise
rvsv
vector
show
rang
growth
attenu
vitro
mark
reduct
pathogen
intranas
inocul
mice
howev
vector
still
display
level
nv
almost
equival
unalt
prototyp
rvsv
vector
intracrani
inocul
mice
addit
one
attenu
vector
contain
g
protein
ct
truncat
highli
attenu
vitro
intranas
inocul
mice
still
caus
moder
level
neuropatholog
nhp
nv
model
j
erik
johnson
et
al
submit
public
observ
indic
previous
describ
attenu
strategi
might
suffici
reduc
rvsv
vector
nv
anim
model
level
would
accept
regulatori
agenc
therefor
addit
strategi
attenu
rvsv
vector
explor
includ
combin
ct
truncat
either
n
gene
rearrang
mncp
mutat
fig
thought
mutat
combin
would
increas
vector
attenu
beyond
level
obtain
use
singl
attenu
strategi
type
gene
rearrang
includ
g
gene
shuffl
singli
combin
also
investig
specif
combin
ts
mutat
also
develop
effort
ensur
tight
shutoff
viral
replic
nonpermiss
temperatur
retain
high
level
transcript
activ
fig
attenu
rvsv
vector
plaqu
size
onestep
growth
kinet
serv
initi
measur
replic
effici
attenu
combin
mutant
vector
show
signific
growth
attenu
vitro
test
nv
mice
intracrani
inocul
rout
inocul
chosen
signific
differ
virul
highli
attenu
vector
often
appar
futur
approach
rvsv
attenu
combin
attenu
strategi
may
extend
rang
attenu
rvsv
vector
test
achiev
optimum
balanc
safeti
immunogen
n
gene
shuffl
may
combin
either
g
protein
ct
truncat
mncp
mutat
individu
gene
transloc
g
may
combin
attenu
strategi
provid
optim
attenu
phenotyp
novel
combin
ts
mutat
may
also
produc
rvsv
vector
replic
well
core
bodi
temperatur
may
suit
intranas
vaccin
deliveri
intranas
inocul
measur
intracrani
inocul
due
exquisit
sensit
vsv
infect
rout
result
mortal
morbid
use
calcul
lethal
dose
ld
vector
data
use
defin
rank
order
vector
attenu
although
murin
nv
model
tractabl
provid
sensit
mean
rank
rvsv
vector
nv
addit
nv
studi
also
carri
ferret
nhp
evalu
vector
safeti
ferret
use
diseas
model
studi
influenza
viru
natur
suscept
infect
display
mani
diseas
symptom
seen
human
ferret
nv
model
recent
develop
compon
influenza
viru
particl
induc
signific
neuropatholog
nhp
intracrani
inocul
absenc
viral
replic
unpublish
data
ferret
nv
model
might
better
indic
nv
neurotrop
potenti
nhp
human
rvsv
vector
safeti
also
assess
intranas
intracrani
inocul
ferret
absenc
clearli
defin
marker
ferret
nv
ld
chang
brain
histopatholog
profil
use
assess
extent
injuri
associ
rvsv
vector
data
murin
nv
immunogen
studi
ferret
nv
studi
use
identifi
promis
candid
vector
nv
test
nhp
studi
perform
prototyp
rvsv
vector
nhp
nv
studi
uvinactiv
rvsv
use
control
measur
baselin
patholog
result
inject
procedur
potenti
injuri
effect
viral
compon
inoculum
control
import
stringent
nv
test
novel
replicationcompet
vaccin
candid
inject
even
innocu
materi
directli
brain
lead
cell
necrosi
around
needl
track
lowlevel
inflammatori
respons
throughout
cn
typic
two
major
type
injuri
result
intrathalam
inocul
replicationcompet
viru
inflammatori
respons
stimul
presenc
foreign
materi
brain
mediat
cytokin
infiltr
leukocyt
tissu
necrosi
result
cell
death
caus
viral
replic
specif
distinct
neuron
necrosi
inflammatori
respons
import
neuron
cell
necrosi
thought
irrevers
process
result
perman
neurolog
deficit
inflammatori
respons
typic
resolv
time
usual
without
perman
sequela
therefor
rvsv
vector
produc
minim
mild
inflammatori
respons
brain
would
strongli
favor
caus
necrot
lesion
expect
attenu
rvsv
vector
current
develop
caus
minim
inflammatori
respons
nhp
cn
intrathalam
inocul
retain
immunogen
one
vector
consid
futur
clinic
evalu
rvsv
vector
attenu
enhanc
safeti
addit
measur
maintain
increas
immunogen
may
requir
rel
flexibl
rvsv
vector
system
rel
eas
genet
manipul
allow
potenti
improv
immunogen
vector
sever
approach
exploit
increas
immunogen
includ
enhanc
foreign
antigen
express
reduct
antivector
immun
coexpress
cytokin
immunomodul
vivo
target
dendrit
cell
heterolog
primeboost
vaccin
regimen
ideal
viral
vector
use
vaccin
ration
design
immunogen
direct
away
vectorspecif
antigen
toward
express
foreign
antigen
therebi
maxim
immunogen
target
antigen
minim
immunogen
vector
antigen
antivector
immun
limit
abil
boost
respons
may
limit
use
vector
backbon
sever
vaccin
target
might
especi
relev
immunotherapeut
approach
persist
infect
hiv
hsv
hcv
repetit
boost
may
requir
control
infect
one
potenti
approach
shift
focu
immun
respons
toward
express
foreign
antigen
away
vsv
antigen
take
advantag
transcript
gradient
vsv
describ
earlier
prototyp
rvsv
vector
develop
rose
et
al
posit
gene
express
foreign
antigen
toward
viral
genom
done
promot
effici
rescu
cdna
maintain
viral
replic
fit
howev
due
transcript
gradient
posit
foreign
gene
toward
genom
reduc
express
foreign
antigen
rel
four
vsv
proxim
gene
product
therefor
futur
rvsv
vector
design
foreign
antigen
gene
vsv
genom
posit
therebi
maxim
express
foreign
antigen
posit
foreign
gene
first
posit
genom
also
attenu
effect
viru
growth
viral
gene
transloc
away
transcript
promot
reduc
express
one
potenti
limit
viral
vector
preexist
immun
vector
addit
primari
immun
respons
vector
often
limit
effect
subsequ
booster
immun
small
anim
model
nhp
strong
serotypespecif
neutral
antibodi
respons
gener
g
protein
vsv
singl
inocul
presenc
neutral
antibodi
preclud
use
ident
rvsv
vector
boost
vector
anim
presum
effect
vaccin
human
circumv
neutral
antibodi
creat
vector
boost
rose
et
al
develop
rvsv
glycoprotein
exchang
vector
encod
n
p
l
gene
vsv
ind
serotyp
gene
express
vsv
ind
serotyp
g
protein
substitut
either
gene
express
vsv
nj
serotyp
g
protein
gene
g
protein
relat
vesiculoviru
chandipura
viru
glycoprotein
exchang
vector
circumv
neutral
antibodi
respons
g
protein
possibl
cell
respons
n
p
l
protein
might
restrict
viru
replic
limit
abil
vector
boost
respons
gener
complet
rvsv
nj
serotyp
vector
attempt
due
potenti
crossreact
cytotox
tlymphocyt
respons
ind
nj
vsv
serotyp
howev
addit
virus
vesiculoviru
genu
could
use
suppli
g
gene
futur
rvsv
g
protein
exchang
vector
multipl
boost
vector
desir
attach
glycoprotein
exchang
manner
introduc
new
gene
vector
may
alter
vector
phenotyp
therefor
care
safeti
test
must
conduct
advanc
vector
clinic
trial
chang
rvsv
serotyp
may
provid
abil
boost
relat
vector
robust
boost
may
possibl
complet
heterolog
viral
vector
nonvir
deliveri
system
plasmid
dna
protein
subunit
bacteri
vector
studi
mice
conduct
vector
express
hiv
env
gag
show
boost
rvsvprime
anim
vacciniabas
vector
produc
fivefold
increas
peak
hivspecif
cell
respons
rel
mice
boost
rvsv
glycoprotein
exchang
vector
follow
studi
ramsburg
et
al
compar
effect
singl
primeboost
immun
regimen
macaqu
consist
labadapt
g
protein
exchang
vsv
vector
express
shiv
env
gag
pol
protein
protocol
consist
labadapt
rvsv
vector
prime
follow
singl
boost
modifi
vaccinia
viru
ankara
mva
express
shiv
protein
macaqu
prime
rvsv
vector
express
shiv
protein
boost
mva
vector
express
shiv
protein
mount
increas
immun
respons
rel
anim
boost
vsv
exchang
vector
howev
due
small
number
macaqu
group
differ
achiev
statist
signific
nevertheless
intraven
shiv
challeng
mvaboost
macaqu
demonstr
log
reduct
peak
viral
load
clear
challeng
viru
faster
preserv
cell
count
greater
extent
macaqu
receiv
vsv
g
protein
exchang
vector
collect
data
suggest
g
protein
exchang
rvsv
vector
circumv
vsvspecif
neutral
antibodi
boost
vaccinespecif
immun
respons
vaccinespecif
immunogen
efficaci
substanti
improv
boost
heterolog
viral
vector
recent
demonstr
prime
seri
intramuscular
inject
plasmid
dna
encod
sivgag
effect
enhanc
immunogen
postchalleng
efficaci
two
intranas
dose
rvsv
express
hivenv
sivgag
rhesu
macaqu
result
demonstr
plasmid
dna
prime
vaccin
regimen
significantli
increas
sivgagspecif
cellmedi
humor
immun
respons
significantli
lower
viral
load
postshiv
challeng
rel
macaqu
receiv
rvsv
vector
immun
addit
plasmid
dna
prime
regimen
also
tend
increas
preserv
peripher
blood
cell
reduc
incid
aidslik
diseas
symptom
death
associ
shiv
infect
although
achiev
statist
signific
due
rel
small
number
macaqu
use
per
group
analysi
immun
correl
protect
shiv
challeng
reveal
shivspecif
elispot
respons
elicit
vaccin
correl
postchalleng
clinic
outcom
thu
higher
shivspecif
cellmedi
immun
respons
elicit
dna
primervsv
boost
vaccin
regimen
associ
increas
mainten
cell
reduct
plasma
shiv
viral
load
rvsv
sivgag
vaccin
given
alon
substanti
lower
shivspecif
cellmedi
immun
respons
elicit
postchalleng
protect
afford
immun
reduc
vector
base
rvsv
platform
demonstr
safeti
immunogen
clinic
trial
import
assess
combin
use
heterolog
primeboost
vaccin
regimen
maxim
potenti
may
addit
benefit
gain
creat
rvsv
vector
express
heterolog
viral
attach
glycoprotein
effort
use
rvsv
vaccin
vector
human
diseas
mani
group
either
replac
vsv
g
protein
coexpress
glycoprotein
target
human
pathogen
includ
hantaviru
test
anim
model
vector
elicit
immun
respons
direct
express
foreign
glycoprotein
recent
nhp
immun
rvsv
vector
express
glycoprotein
either
marburg
ebola
virus
protect
diseas
challeng
pathogen
moreov
like
replac
vsv
g
protein
filovirus
glycoprotein
alter
rvsv
vector
tissu
tropism
could
readili
target
dendrit
cell
filovirus
known
retarget
rvsv
vector
could
design
express
addit
foreign
antigen
unrel
pathogen
serv
either
prime
boost
vector
along
rvsv
ind
nj
serotyp
vector
retarget
glycoprotein
exchang
markedli
alter
viru
phenotyp
cell
tropism
new
rvsv
vector
type
requir
extens
safeti
studi
clinic
assess
one
advantag
use
viral
vector
vaccin
believ
act
adjuv
stimul
innat
immun
respons
bind
viral
compon
pathogen
recognit
receptor
host
cell
specif
vsv
singlestrand
rna
believ
bind
tolllik
infect
plasmacytoid
dendrit
cell
essenti
initi
type
ifn
respons
innat
respons
furthermor
ribonucleoprotein
complex
vsv
shown
activ
cellular
kinas
involv
product
type
ifn
spite
adjuv
activ
vsv
rvsv
vector
need
attenu
may
help
enhanc
immunogen
express
proinflammatori
cytokin
coadministr
small
molecul
adjuv
immunomodul
sever
rvsv
vector
alreadi
gener
express
variou
cytokin
vector
weak
adjuv
effect
posit
result
rvsv
vector
express
granulocytemacrophag
colonystimul
factor
gmcsf
report
proinflammatori
cytokin
express
antigenpres
cell
heterodim
drive
develop
respons
orf
fusion
protein
insert
replicationrestrict
rvsv
vector
lack
gene
g
protein
coadminist
weakli
antigen
listeri
antigen
enhanc
cell
respons
determin
listerialspecif
secret
b
cell
respons
determin
listeriaspecif
igg
titer
gener
mice
moreov
coadministr
listeri
antigen
confer
protect
lethal
intraperiton
listeri
challeng
gmcsf
recruit
activ
antigenpres
cell
includ
macrophag
dendrit
cell
rvsv
vector
express
murin
gmcsf
first
posit
viral
genom
shown
attenu
viral
pathogenesi
mice
retain
immun
respons
n
protein
vsv
memori
respons
vsv
n
also
slightli
enhanc
mice
immun
compar
vsv
n
respons
mice
immun
rvsv
express
green
fluoresc
protein
still
determin
coadministr
along
rvsv
vector
express
foreign
antigen
modul
respons
antigen
develop
procedur
recoveri
virus
order
mononegaviral
genom
cdna
creat
opportun
util
group
virus
vaccin
vector
prevent
treatment
wide
rang
human
diseas
vsv
one
moststudi
nonseg
neg
strand
rna
virus
foremost
among
potenti
vaccin
vector
group
virus
vsv
natur
found
insect
livestock
consid
human
pathogen
low
seropreval
human
popul
small
simpli
organ
viral
genom
alter
stabli
express
one
foreign
protein
result
viral
vector
amplifi
high
titer
approv
cell
line
viru
broad
host
rang
rvsv
vector
serotyp
chang
simpli
switch
surfac
glycoprotein
vesiculoviru
serotyp
vsv
replic
exclus
cytoplasm
infect
cell
persist
vivo
viral
nucleic
acid
integr
host
genom
dna
desir
properti
led
develop
rvsv
potenti
vaccin
vector
sign
vsv
infect
livestock
usual
restrict
occurr
vesicular
lesion
around
mouth
nose
teat
coronari
band
hoov
typic
resolv
day
without
seriou
consequ
howev
histor
data
show
vsv
could
lethal
mice
neurovirul
inject
directli
brain
mice
livestock
nhp
therefor
investig
potenti
neurotrop
nv
prototyp
rvsv
vaccin
vector
exploratori
nv
test
nhp
carri
result
test
indic
prototyp
vaccin
vector
requir
attenu
clinic
evalu
varieti
differ
attenu
strategi
combin
thereof
evalu
defin
accept
attenu
phenotyp
sensit
mous
ld
nv
model
use
rank
order
rvsv
vector
attenu
level
vector
caus
minim
morbid
mortal
mous
model
test
ferret
nhp
nv
model
assess
residu
vector
virul
vector
caus
minim
degre
neuropatholog
target
clinic
evalu
balanc
satisfactori
level
safeti
adequ
immunogen
attenu
rvsv
vector
challeng
howev
upregul
antigen
express
gene
posit
effect
may
enhanc
immunogen
compens
increas
attenu
viru
replic
abil
coexpress
molecular
adjuv
rvsv
vector
may
improv
antigen
protein
combin
vaccin
vector
vaccin
vector
includ
plasmid
dna
heterolog
primeboost
regimen
also
provid
anoth
promis
approach
enhanc
immun
respons
